Clinical Trials Directory

Trials / Terminated

TerminatedNCT00617656

Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma

Multicenter Phase III, Randomized Study to Evaluate Treatment Customized According to RAP80 and BRCA1 Assessment in Patients With Advanced Non-small-cell Lung Cancer

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
382 (actual)
Sponsor
Spanish Lung Cancer Group · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Primary objective: · Progression free survival. Secondary objectives: * Assess Overall survival of both treatment groups. * Assess Tumor response rate using RECIST criteria * Assess Toxicity profile of patients enrolled in the study. * Exploratory evaluation of potential genetic markers of response or resistance to chemotherapy.

Detailed description

Study population: Patients with advanced non-small-cell lung cancer who have not received treatment for the disease at this stage and who have a good performance status (ECOG 0-1) and measurable disease (at least one target lesion according to RECIST criteria). Duration of treatment: Six chemotherapy cycles will be given. The duration of every cycle will be 21 days. If the treatment is beneficial, it may be prolonged to a total of 8 cycles at the discretion of the investigator. Calendar and planned finalization date: The approximate duration of the study is 3 years of recruitment followed by 1 year of follow-up.

Conditions

Interventions

TypeNameDescription
DRUGCisplatin, DocetaxelDocetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
DRUGGemcitabine, CisplatinGemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
DRUGDocetaxel, CisplatinDocetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
DRUGDocetaxelDocetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6

Timeline

Start date
2008-02-01
Primary completion
2015-04-01
Completion
2015-04-01
First posted
2008-02-18
Last updated
2024-01-30
Results posted
2024-01-30

Locations

44 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT00617656. Inclusion in this directory is not an endorsement.